Kineta (KA) announced that it has completed the enrollment of new patients into the monotherapy arm of the VISTA-101 phase 1 clinical trial evaluating KVA12123, Kineta’s novel VISTA blocking immunotherapy, in patients with advanced solid tumors. The monotherapy portion of the trial enrolled patients in 6-dose cohorts ranging from 3mg to 1000mg every two weeks and no dose limiting toxicities or cytokine related adverse events have been observed in the study. The Company is continuing to enroll patients into cohorts evaluating KVA12123 in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Bicara Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Merck’s Keytruda met primary endpoint in Phase 3 carcinoma study
- J&J trial miss may be viewed positively for CG Oncology, says BofA
- AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
- Merck price target lowered to $140 from $142 at Barclays